

CV Therapeutics

[View the current CV Therapeutics Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/3140-CV+Therapeutics.html)

(<http://www.bioportfolio.com/biocorporate/3140-CV+Therapeutics.html>)

Contact Details:

3172 Porter Drive

Palo Alto

CA

94304

United States of America

Tel: 650-384-8500

Fax: 650-858-0390

Email: webmaster@cvt.com

CV Therapeutics, Inc. (CVT), headquartered in Palo Alto, California, is a biopharmaceutical company focused on the discovery, development, and commercialization of new small molecule drugs for the treatment of cardiovascular diseases. We apply advances in molecular biology and genetics to identify mechanisms of cardiovascular diseases and targets for drug discovery. As a pioneer in the field of molecular cardiology, CV Therapeutics strives to discover new solutions for the unmet medical needs of patients. The company employs nearly 700 professionals, including a cardiovascular sales force of approximately 300 field-based individuals. Nearly 20 percent of employees based in our Palo Alto headquarters hold doctoral degrees, including MDs, PhDs, and PharmDs. Key drivers of our business are to: Identify, develop, and commercialize drugs primarily for cardiovascular disease, Focus on small molecule drug candidates, In-license cardiovascular products with unique potential, and Commercialize products through concentrated sales and marketing efforts.

Recent Publications by CV Therapeutics:



- [Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion.](#)
*We tested the effect of the antianginal agent ranolazine on ventricular...*13th November, 2009
CV Therapeutics, Inc., 3172 Porter Dr., Palo Alto, CA 94304, USA.- *Am J Physiol Heart Circ Physiol.* 2009 Nov;297(5):H1923-9. Epub 2009 Sep ([DOI Direct Link](#))
- [A1 adenosine receptor: role in diabetes and obesity.](#)
*Adenosine mediates its diverse effects via four subtypes (A(1), A(2A),...*25th September, 2009
Department of Pharmacological Sciences, CV Therapeutics Inc., Palo Alto,- *Handb Exp Pharmacol.* 2009;(193):271-95. ([DOI Direct Link](#))
- [Recent developments in A2B adenosine receptor ligands.](#)

- A selective, high-affinity A(2B) adenosine receptor (AR) antagonist will...* 25th September, 2009
Department of Medicinal Chemistry, CV Therapeutics Inc., Palo Alto, CA- *Handb Exp Pharmacol.* 2009;(193):99-122. ([DOI Direct Link](#))
- [The late Na⁺ current \(I_{Na}\) inhibitor ranolazine attenuates effects of palmitoyl-L-carnitine to increase late I_{Na} and cause ventricular diastolic dysfunction.](#)
Palmitoyl-L-carnitine (PC), an ischemic metabolite, causes cellular Na(+)...20th August, 2009
CV Therapeutics Inc, Palo Alto, California, USA.- *J Pharmacol Exp Ther.* 2009 Aug;330(2):550-7. Epub 2009 Apr 29. ([DOI Direct Link](#))
 - [Suppression of heavy drinking and alcohol seeking by a selective ALDH-2 inhibitor.](#)
BACKGROUND: Inherited human aldehyde dehydrogenase 2 (ALDH-2) deficiency... 14th August, 2009
CV Therapeutics, Palo Alto, CA, USA.- *Alcohol Clin Exp Res.* 2009 Nov;33(11):1935-44. Epub 2009 Aug 10. ([DOI Direct Link](#))
 - [Orally bioavailable, liver-selective stearoyl-CoA desaturase \(SCD\) inhibitors.](#)
We discovered a structurally novel SCD (Delta9 desaturase) inhibitor 4a... 18th July, 2009
Department of Medicinal Chemistry, CV Therapeutics, Inc, Palo Alto, CA- *Bioorg Med Chem Lett.* 2009 Jun 1;19(11):3050-3. Epub 2009 Apr 8. ([DOI Direct Link](#))
 - [Novel, potent, selective, and metabolically stable stearoyl-CoA desaturase \(SCD\) inhibitors.](#)
We identified a series of structurally novel SCD (Delta9 desaturase)... 16th June, 2009
Department of Medicinal Chemistry, CV Therapeutics, Inc., Palo Alto, CA- *Bioorg Med Chem Lett.* 2009 Apr 1;19(7):2048-52. Epub 2009 Feb 8. ([DOI Direct Link](#))
 - [Block of tetrodotoxin-sensitive, Na\(V\)1.7 and tetrodotoxin-resistant, Na\(V\)1.8, Na⁺ channels by ranolazine.](#)
Evidence supports a role for the tetrodotoxin-sensitive Na(V)1.7 and the... 14th April, 2009
Department of Pharmacological Sciences, CV Therapeutics, Inc., Palo Alto,- *Channels (Austin).* 2008 Nov-Dec;2(6):449-60. Epub 2008 Nov 7.
 - [Sensitive and cost-effective LC-MS/MS method for quantitation of CVT-6883 in human urine using sodium dodecylbenzenesulfonate additive to eliminate adsorptive losses.](#)
CVT-6883, a novel selective A(2B) adenosine receptor antagonist currently... 8th April, 2009
Department of Pre-clinical Development, CV Therapeutics, Inc., 3172 Porter- *J Chromatogr B Analyt Technol Biomed Life Sci.* 2009 Apr 1;877(10):943-7. ([DOI Direct Link](#))
 - [Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine.](#)
BACKGROUND: Quinidine is used to treat atrial fibrillation and ventricular... 8th April, 2009
Pharmacological Sciences, CV Therapeutics, Inc., Palo Alto, California- *Heart Rhythm.* 2008 Dec;5(12):1726-34. Epub 2008 Sep 6. ([DOI Direct Link](#))
 - [Actions of ATX-II and other gating-modifiers on Na\(+\) currents in HEK-293 cells expressing WT and DeltaKPQ hNa\(V\) 1.5 Na\(+\) channels.](#)
Voltage-gated Na(+) channels underlie the action potential upstroke in... 8th April, 2009
Department of Pharmacological Sciences, CV Therapeutics Inc, 3172 Porter- *Toxicol.* 2009 Jan;53(1):78-89. Epub 2008 Nov 1. ([DOI Direct Link](#))
 - [Regadenoson, a novel pharmacologic stress agent for use in myocardial perfusion imaging, does not have a direct effect on the QT interval in conscious dogs.](#)
Our goal was to determine the effect of regadenoson (a novel A2A adenosine... 7th February, 2009
Department of Pharmacology, CV Therapeutics, Inc., Palo Alto, California- *J Cardiovasc Pharmacol.* 2008 Nov;52(5):467-73. ([DOI Direct Link](#))
 - [A1 adenosine receptor agonists and their potential therapeutic applications.](#)
BACKGROUND: The challenges in developing any A(1) adenosine receptor... 8th January, 2009
CV Therapeutics, Inc., Department of Bioorganic Chemistry, 3172 Porter- *Expert Opin Investig Drugs.* 2008 Dec;17(12):1901-10. ([DOI Direct Link](#))
 - [Rapid kinetic interactions of ranolazine with HERG K⁺ current.](#)
Ranolazine, an anti-ischemic agent, inhibits I_{Kr} [encoded by the human... 9th October, 2008
Department of Pharmacological Sciences, CV Therapeutics, Inc., Palo Alto,- *J Cardiovasc Pharmacol.* 2008 Jun;51(6):581-9. ([DOI Direct Link](#))
 - [Progress in the discovery of selective, high affinity A\(2B\) adenosine receptor antagonists as clinical](#)

[candidates.](#)

The selective, high affinity A(2B) adenosine receptor (AdoR) antagonists... 24th June, 2008
Department of Bioorganic Chemistry, CV Therapeutics Inc., 3172 Porter- Purinergic Signal. 2009
Mar;5(1):21-9. Epub 2008 Jun 21. ([DOI Direct Link](#))

Press Releases on CV Therapeutics:

Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: <i>Intranasal Drug Delivery - US Market Trends & Analysis</i> http://www
Reportlinker Adds Veterinary Vaccines - A World Market Analysis	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: <i>Veterinary Vaccines - A World Market Analysis</i> http://www.reportlinker.com
Reportlinker Adds Prostate Cancer Therapeutics - a Global Market Perspective	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: <i>Prostate Cancer Therapeutics - A Global Market Perspective</i> http://www
Reportlinker Adds Regenerative Medicine - Global Market Trends	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: <i>Regenerative Medicine - Global Market Trends</i> http://www.reportlinker.com
Reportlinker Adds Pain Management - Global Trends	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: <i>Pain Management - Global Trends</i> http://www.reportlinker.com/p0164220/Pain

BioNews Results for CV Therapeutics



- [New Antiplatelets vs. Clopidogrel: Ticagrelor Hits, Cangrelor Misses](#)
TCTMD.com: Nov 16 2009 11:31AM Matching: cv therapeutics
- [Japanese drug companies try a taste of Bay Area medicine](#)
Biz Journals: Nov 9 2009 6:25AM Matching: cv therapeutics
- [Japanese drug companies try a taste of Bay Area medicine](#)
San Francisco Business Times: Nov 6 2009 5:48PM Matching: cv therapeutics
- [Appointments update](#)
Pharmafocus: Nov 4 2009 3:21PM Matching: cv therapeutics

- [Appointments update](#)
Pharmafocus: Nov 4 2009 3:20PM Matching: cv therapeutics
- [Gilead \(GILD\): 4-in-1 HIV drug](#)
TheStockAdvisors.com: Nov 3 2009 6:21PM Matching: cv therapeutics
- [UPDATE 2-Astellas, Medivation in prostate-cancer drug pact](#)
Forbes.com: Oct 27 2009 1:46PM Matching: cv therapeutics
- [UPDATE 2-Astellas, Medivation in prostate-cancer drug pact](#)
Reuters: Oct 27 2009 1:35PM Matching: cv therapeutics
- [NewCardio Expert to Present at Cardiac Safety Research Consortium Annual Meeting Dr. Sam George to join government regulators, pharmaceutical industr](#)
Yahoo! Canada: Oct 22 2009 2:46PM Matching: cv therapeutics
- [Morgan Joseph Suggests Buying Shares of Gilead Sciences \(GILD\) on Any Weakness](#)
Street Insider: Oct 21 2009 12:46PM Matching: cv therapeutics
- [Gilead Profit Rises 36%](#)
CNBC: Oct 20 2009 8:39PM Matching: cv therapeutics
- [Gilead Profit Rises 36%, but Shares Fall](#)
CNBC: Oct 20 2009 8:33PM Matching: cv therapeutics
- [Large Cap Biotech Earnings Preview](#)
Cafepharm: Oct 19 2009 10:13AM Matching: cv therapeutics
- [AstraZeneca's CRESTOR approved for treating pediatric patients with HeFH](#)
News-Medical.Net: Oct 19 2009 11:46AM Matching: cv therapeutics
- [Toshiba Introduces Its Next-Generation CV-3D for Infinix Cardiovascular X-ray Systems](#)
Cath Lab Digest: Oct 14 2009 12:09PM Matching: cv therapeutics

CV Therapeutics Clinical Trials:



- [Safety Study of Tecadenoson to Treat Atrial Fibrillation](#)

CV Therapeutics Patents:



- 6930111- [Substituted heterocyclic compounds](#)
- 7115610- [Substituted heterocyclic compounds](#)
- 7125876- [Substituted heterocyclic compounds](#)
- 7125993- [A.sub.2B adenosine receptor antagonists](#)
- 7144871- [Partial and full agonists of A.sub.1 adenosine receptors](#)
- 7144872- [N-pyrazole A.sub.2A receptor agonists](#)
- 7157440- [Partial and full agonists of A1 adenosine receptors](#)

- 7160592- [Polymer coating for medical devices](#)
- 7163928- [Partial and full agonists of A.sub.1 adenosine receptors](#)
- 7183264- [N-pyrazole A2A receptor agonists](#)
- 7189730- [A.sub.2A adenosine receptor antagonists](#)
- 7109330- [Purine inhibitors of cyclin dependent kinase 2 and I.kappa.B-.alpha.](#)
- 7109180- [C-pyrazole A.sub.2A receptor agonists](#)
- 7105665- [A.sub.2B adenosine receptor antagonists](#)
- 6946449- [Partial and full agonists of A1 adenosine receptors](#)
- 6977300- [A2B adenosine receptor antagonists](#)
- 6995285- [ABCA-1 elevating compounds](#)
- 7001909- [Substituted heterocyclic compounds](#)
- 7005425- [Method for treating arrhythmias](#)
- 7022681- [Partial and full agonists of A1 adenosine receptors](#)
- 7022710- [A1 adenosine receptor antagonists](#)
- 7026321- [Substituted heterocyclic compounds](#)
- 7056924- [Substituted heterocyclic compounds](#)
- 7071174- [Method and composition for inhibiting cholesterol esterase](#)
- 7205303- [Substituted heterocyclic compounds](#)
- 7208496- [Substituted heterocyclic compounds](#)
- 7423045- [ABCA1 elevating compounds](#)
- 7432276- [ABCA1 elevating compounds](#)
- 7449473- [Substituted pyrrolo\[3,2-d\]pyrimidin-2,4-diones as A.sub.2b adenosine receptor antagonists](#)
- 7452889- [Substituted heterocyclic compounds](#)
- 7479485- [Method of treating arrhythmias](#)
- 7488720- [A.sub.1 adenosine receptor agonists](#)
- 7514417- [A.sub.1 adenosine receptor agonists](#)
- 7517888- [A.sub.1 adenosine receptor antagonists](#)
- 7521554- [A.sub.2B adenosine receptor antagonists](#)
- 7553823- [C-pyrazole A2A receptor agonists](#)
- 7419709- [Polymer coating for medical devices](#)
- 7407960- [Substituted heterocyclic compounds](#)
- 7381714- [A1 adenosine receptor agonists](#)
- 7238700- [A.sub.2B adenosine receptor antagonists](#)
- 7262176- [Adenosine A.sub.3 receptor agonists](#)
- 7262198- [Substituted heterocyclic compounds](#)
- 7271157- [A.sub.1 adenosine receptor agonists](#)
- 7271169- [Substituted heterocyclic compounds](#)
- 7300923- [Partial and full agonists of A1 adenosine receptors](#)
- 7304070- [A.sub.2B adenosine receptor antagonists](#)
- 7317017- [A.sub.2B adenosine receptor antagonists](#)
- 7351535- [Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter protein ABC1](#)
- 7364768- [Polymer coating for medical devices](#)
- 7582617- [Myocardial perfusion imaging method](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core

information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

